Skip to main content
$9.06 $0.42 (4.9%)

04:00 PM EST on 12/01/23

Aurinia Pharmaceuticals (NASDAQ:AUPH)

CAPS Rating: 2 out of 5

Current Price $9.06 Mkt Cap $1.3B
Open $8.59 P/E Ratio -16.73
Prev. Close $9.06 Div. (Yield) $0.00 (0.0%)
Daily Range $8.42 - $9.06 Volume 2,226,743
52-Wk Range $4.07 - $12.43 Avg. Daily Vol. 1,961,038


How do you think NASDAQ:AUPH will perform against the market?

Add Stock to CAPS Watchlist

All Players

50 Outperform
6 Underperform

All-Star Players

10 Outperform
1 Underperform

Wall Street

0 Outperform
0 Underperform

Top NASDAQ:AUPH Bull/Bear Pitches

The best Bull and Bear pitches based on recency and number of recommendations.

Top Bull Pitch

There are no pitches that meet the Top Bull criteria. Explain

If this upsets you, start recommending pitches below!

zzlangerhans (98.77)
Submitted October 06, 2016

Aurinia wins the comeback kid award after rebounding to 5.5 just six weeks after crashing to 1.73 on word of a substantial mortality imbalance favoring control in the AURA-LV phase IIb trial of voclosporin for lupus nephritis. Aurinia insists that… More


Fools bullish on NASDAQ:AUPH are also bullish on:

Fools bearish on NASDAQ:AUPH are also bearish on:

Recent Community Commentary

Read the most recent pitches from players about AUPH.


Member Avatar Zvika (20.27) Submitted: 1/26/2021 6:59:16 PM : Outperform Start Price: $18.15 NASDAQ:AUPH Score: -71.43

Lupkynis 1st oral drug to treat lupus nephritis. May be a game changer. Also likely takeover candidate


Member Avatar mdriver78 (66.09) Submitted: 7/29/2020 9:51:19 AM : Outperform Start Price: $13.23 NASDAQ:AUPH Score: -74.56

Aurinia has successfully advanced a drug for this condition through Phase 3 trials. The company’s drug, called voclosporin, works by inhibiting an enzyme called calcineurin. Calcineurin activates inflammatory molecules and T cells, and drugs of this class have been used to treat a range of autoimmune diseases.

Voclosporin, however, has a number of advantages over other drugs of this class. These include increased potency and lower diabetes risk. Moreover, after a year of treatment, patients in the Phase 3 trial were almost twice as likely (22% vs. 40.8%) to achieve a positive renal response over patients receiving the current standard-of-care treatment.[2]

Patients were evaluated using urine analysis and voclosporin patients were much more likely to see a reduction of biomarkers like proteins in urine, to healthier levels.

That’s important. This indicates that the drug is reducing kidney inflammation and helping to protect the vital organ from damage.

These good results released late last year enabled Aurinia to file a New Drug Application with the FDA earlier this year. The regulator has not only accepted this small drug company’s application, but it’s agreed to grant it Priority Review status. This indicates that the FDA considers this drug to be important enough to warrant an expedited review process.

Priority Review sets a six-month target for a final decision on whether or not a new drug is approved. Aurinia announced that its application was accepted on June 21, so that means we can expect an FDA decision by Jan. 22, 2021.


Member Avatar odocoileus (< 20) Submitted: 6/9/2020 12:11:44 PM : Outperform Start Price: $6.19 NASDAQ:AUPH Score: -44.44

While nothing is a slam-dunk with FDA, AUPH is very likely to get approval for Voclosporin. The biggest risk is a CRL due to manufacturing issues or a request for additional data. That should only cause a delay, however, and an eventual approval is likely. I would expect a run up to approval, with the share price trading sideways for a quarter or two during launch. Given the addressable market and the lack of competition, though, uptake of the drug is likely, and the this should double in the next couple of years.


Find the members with the highest scoring picks in AUPH.

Score Leader


usubanas2 (79.73) Score: +452.49

The Score Leader is the player with the highest score across all their picks in AUPH.

Member Name Member
Call Time
Score Commentary
jack0071 64.37 12/28/2016 Outperform 5Y $2.14 +318.22% +102.63% +215.59 0 Comment
ChanceClub 84.10 8/17/2020 Underperform 5Y $14.19 -36.93% +35.85% +72.78 0 Comment
mmr23 < 20 3/7/2017 Underperform NS $6.82 +31.23% +93.50% +62.27 1 Comment
shredlee 53.65 2/15/2017 Outperform 1Y $3.58 +150.00% +96.16% +53.84 0 Comment
eyezie1 < 20 11/21/2016 Outperform 5Y $3.58 +149.94% +109.12% +40.83 0 Comment
Under5 55.47 10/11/2019 Outperform 5Y $4.70 +90.43% +54.96% +35.47 0 Comment
Doppelganger 46.74 10/10/2016 Underperform 5Y $4.90 +82.65% +112.39% +29.74 0 Comment
WildShaman 78.47 7/9/2018 Underperform 5Y $5.70 +57.02% +66.01% +8.99 0 Comment
PayrollGeek < 20 8/20/2018 7/29/2023 Outperform 3Y $5.29 +69.14% +60.61% +8.53 0 Comment
NextGenStock < 20 8/14/2018 7/19/2023 Outperform 5Y $5.26 +70.15% +62.27% +7.88 0 Comment

Wall Street

See what the Wall Street professionals think, according to their public statements and filings.

There are no Wall Street tracker picks for AUPH.